Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • English
    • Deutsch
    • Français
    • Italiano
    • Português
    • Español
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Dermatology
      • Atopic dermatitis and psoriasis news
      • Dermatology News
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
      • Forum Gastroenterology
      • Ozanimod: ulcerative colitis
      • Reflux Update
    • Immunology
      • Primary immunodeficiency – exchange of experience
    • Vaccinate
      • Herpes zoster
    • Infektiologie
    • Neurology
      • EXPERT ULTRASONIC: Introduction to ultrasound-guided injection
      • MS News
      • MS Therapy in Transition
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Practice Management
      • Aargau Cantonal Bank
      • Claraspital
    • Psychiatry
      • Geriatric Psychiatry
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Majore depression

Ketamine-containing nasal spray approved in Switzerland

    • General Internal Medicine
    • Market & Medicine
    • Psychiatry and psychotherapy
    • RX
    • Studies
  • 2 minute read

Following the EU, Switzerland has also recently approved a nasal spray based on the active ingredient ketamine, which is known as a party drug. The preparation can be used as an add-on in case of therapy resistance.

The drug Spravato® (esketamine) is approved in combination with an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) for adults with treatment-resistant major depression [1]. Treatment resistance is defined as a lack of response to at least two different antidepressants [2]. The approval is based on five phase III studies: three short-term studies, one long-term safety study, and one randomized relapse prevention study [2].

Very rapid onset of action

The great advantage of esketamine is that it acts comparatively quickly. In pivotal trials, more than 1600 patients over the age of 18 years with treatment-resistant depression received esketamine nasal spray combined with a newly administered oral antidepressant [2]. In the short-term studies, a clinically significant response was measurable in the verum group up to 28 days after baseline.  Response was defined as a reduction in total Montgomery-Asberg Depression Rating Scale (MADRS) score of at least 50% from baseline in the induction phase. In the multicenter, randomized, double-blind, active-controlled, long-term relapse prevention trial, esketamine nasal spray combined with an antidepressant reduced the risk of relapse by 70% in patients with stable response compared with the placebo group. In patients in stable remission, the risk of recurrence decreased by 51%. The long-term safety study found that even with up to 52 weeks of therapy, esketamine nasal was generally well tolerated.

The antidepressant effect probably occurs via antagonism at the NMDA receptor. This provides a transient increase in glutamate release that leads to increased stimulation of the AMPA receptor and subsequently increased neurotrophin-induced signal transduction, which may contribute to restored synaptic function in brain regions responsible for mood and emotion regulation [3].

Blood pressure control recommended

The nasal spray is a single-use applicator containing a total of 28 mg of esketamine divided into two sprays (one spray per nostril). The nasal spray is intended for use by the patient himself/herself under the supervision of healthcare professionals, according to the respective dosage recommendations. Before using the nasal spray, the patient’s blood pressure must be measured. If baseline blood pressure is elevated, the risks associated with short-term elevated blood pressure levels must be weighed against the benefits of treatment. The spray must not be used if increased blood pressure or increased intracranial pressure poses a serious risk. Blood pressure should be checked approximately 40 minutes after application of Spravato® and again thereafter at clinical discretion [3].

Source: Janssen-Cilag International

 

Literature:

  1. Mahase E: Esketamine is approved in Europe for treating resistant major depressive disorder. BMJ 2019; 367: l7069.
  2. European Medicines Agency. Esketamine nasal spray Summary of Product Characteristics, www.ema.europa.eu/en/medicines
  3. Siebenand S: Esketamine nasal spray approved for depression. Pharmaceutical Journal, Dec. 23, 2019, www.pharmazeutische-zeitung.de
  4. Swissmedics: Spravato®, nasal spray (esketaminum), www.swissmedic.ch

 

HAUSARZT PRAXIS 2020; 15(4): 27

Autoren
  • Mirjam Peter, M.Sc.
Publikation
  • HAUSARZT PRAXIS
Related Topics
  • AMPA receptor blood pressure control
  • Esketamine
  • Ketamine-containing
  • MADRS
  • Majore depression
  • Montgomery-Asberg Depression Rating Scale
  • Nasal spray
  • NMDA receptor
  • SNRI
  • Spravato®
  • SSRI
  • treatment-resistant
Previous Article
  • Psychooncology

Communication is the key to adherence

  • Education
  • General Internal Medicine
  • Prevention and health care
  • RX
View Post
Next Article
  • Digitization

The trend is toward telemedicine – not only because of COVID-19

  • General Internal Medicine
  • Infectiology
  • News
  • Prevention and health care
  • RX
View Post
You May Also Like
View Post
  • 4 min
  • Journal Club

Stargardt’s disease: groundbreaking gene therapy study gives hope

    • Education
    • General Internal Medicine
    • Genetics
    • Ophthalmology
    • RX
    • Studies
View Post
  • 4 min
  • Surgical interventions

What is necessary, what can be dispensed with?

    • Congress Reports
    • Gynecology
    • RX
    • Studies
    • Surgery
View Post
  • 6 min
  • Case study

Pemphigus – from diagnosis to therapy

    • Cases
    • Dermatology and venereology
    • Education
    • RX
    • Studies
View Post
  • 4 min
  • Efficacy, safety and practical application

Phytotherapeutic options for endometriosis

    • General Internal Medicine
    • Gynecology
    • Pharmaceutical medicine
    • Phytotherapy
    • RX
    • Studies
View Post
  • 5 min
  • Anxiety disorders

New study on lavender oil extract in a long-term setting

    • RX
    • Education
    • General Internal Medicine
    • Pharmaceutical medicine
    • Phytotherapy
    • Psychiatry and psychotherapy
    • Studies
View Post
  • 12 min
  • Evidence, effectiveness and practical implications

Medicinal plants for allergic rhinitis

    • RX
    • Allergology and clinical immunology
    • Education
    • General Internal Medicine
    • ORL
    • Pharmaceutical medicine
    • Phytotherapy
    • Studies
View Post
  • 15 min
  • Current status and future prospects

Cell and gene therapies in modern cardiology

    • Cardiology
    • Education
    • Genetics
    • RX
    • Studies
View Post
  • 14 min
  • Patient-oriented recommendations for action

Effect of heat on diabetes technology

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Prevention and health care
    • Studies
Top Partner Content
  • Forum Gastroenterology

    Zum Thema
  • Herpes zoster

    Zum Thema
  • Dermatology News

    Zum Thema
Top CME content
  • 1
    Pathomechanisms, secondary prevention and treatment options
  • 2
    Effect of heat on diabetes technology
  • 3
    Improved quality of care aims for satisfied patients
  • 4
    Dr. ChatGPT: Large language models in everyday clinical practice
  • 5
    Examinations and considerations before therapy

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.